RxDoctor Payments Data

Mark Newton, MD

Urology · Waterloo, IANPI 1790929354

Payments from drug & device makers

$1,424in general payments, 2019–2025

Across 64 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$541
  • Boston Scientific$263
  • Calyxo, Inc.$110
  • KARL Storz Endoscopy-america$104
  • AbbVie$99
  • Laborie Medical Technologies Corp.$89
  • plus $218 from 4 others

What the payments were for

  • Food & beverage$1,36996%
  • Education$554%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,424 in reported general payments places this provider in the 45th percentile of 114 urology providers in Iowa.

See all urology providers in Iowa

Medicare billing

Part B allowed, 2024
$243,886
Medicare patients
601
Services billed
3,670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron157$102,949
GemtesaVibegron136$76,842
Tamsulosin Hcl464$7,277
Potassium Citrate ErPotassium Citrate64$6,927
Silodosin71$3,609
Finasteride299$3,303
Oxybutynin Chloride ErOxybutynin Chloride70$3,296
Solifenacin Succinate106$3,207
Methenamine Hippurate51$2,792
Estradiol40$2,263
Fesoterodine Fumarate ErFesoterodine Fumarate28$2,169
Trospium Chloride15$1,173
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst51$856
Dutasteride16$740
Oxybutynin Chloride85$713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$55$102,949157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 114 urology providers in Iowa.

Other urology in Waterloo

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →